1. Duran-Sandoval D, Thomas AN, Bailleul B, Fruchart JC, Staels B (2003) Pharmacologie des agonistes PPARα et PPARγ et des activateurs mixtes en déveleppement clinique. Med Sci 19:819–825
2. Rubenstrunk A, Hanf R, Hum DW, Fruchart JC, Staels B (2007) Safety issues and prospects for future generations of PPAR modulators. Biochem Biophys Acta 1771:1065–1081
3. El-Hage J (2004) Preclinical and clinical safety assessments for PPAR agonists. http://www.fda.gov/cder/present/DIA2004/Elhage.ppt . Accessed 1 March 2005
4. Food and Drug Administration (2010) FDA drug safety communication: ongoing safety review of actos (pioglitazone) and potential increased risk of bladder cancer after two years exposure. http://www.fda.gov/Drugs/DrugSafety/ucm226214.htm. . Accessed 1 October 2010
5. Hillaire-Buys D, Faillie JL, Montastruc JL (2011) Pioglitazone and bladder cancer. Lancet 378:1543–1544